Programme

Draft programme, subject to change

Thursday 14th March 2019

13:00
Registration and Lunch
13:50
Biomarkers in NASH/HCC
Professor Helen Reeves,  Newcastle University
14:10
Research update Leeds
Dr Ian Rowe,   University of Leeds
14:25
Research update Cambridge
Dr Matt Hoare, Cambridge Cancer Centre
14:40
Research update Liverpool
Tim Cross, Royal Liverpool University Hospital
14:55
Open Forum - Potential Collaborations
15:10
Break
15:30
The future outlook for HCC therapy and research questions that still need answering
Dr Rohini Sharma,  Imperial College. London
15:50
HCC management and outcomes – the perspective from Ireland 
Dr Diarmaid Houlihan, St Vincent’s University Hospital
16:10
The therapeutic potential of NK cells in HCC
Prof Salim Khakoo,  University of Southampton
16:30
SBRT in HCC – data from CtE and review of clinical trial proposals
James Good, Birmingham
Maria Hawkins, Oxford
Rebecca Goody, Leeds
16:30
Cell therapy for HCC
Dr Stuart Curbishley, University of Birmingham

Oral Presentations – presented on Friday 15th March 2019
Oral Code Time Title, presenter and presenter’s organisation
O1 11.05
|
11.15
THE NATIONAL LIVER OFFERING SYSTEM EFFECTIVELY PREVENTS NAMED PATIENT OFFERS OF
TRANSPLANTATION TO PATIENTS WITH HEPATOCELLULAR CARCINOMA
I.A. Rowe, Leeds Liver Unit & Leeds Institute for Data Analytics, St James University Hospital & University of Leeds, UK
O2 12.25
|
12.35
NON-AUTONOMOUS INDUCTION OF ENDOTHELIAL ICOSL MAY UNDERPIN IMMUNE-MEDIATED
SENESCENCE SURVEILLANCE – M. Hoare, Cancer Research UK Cambridge Institute, University of Cambridge,
Department of Medicine, University of Cambridge, UK
O3 14.35
|
14.45
A UK AUDIT OF HCC PATIENTS UNDERGOING BIOPSY FOR SORAFENIB THERAPY – T. Meyer, Department
of Oncology, Royal Free London NHS Foundation Trust, London, UK; UCL Cancer Institute, London, UK
O4 14.45
|
14.55
LONGITUDINAL MONITORING OF CELL-FREE DNA PREDICTS FOR TRANSARTERIAL CHEMOEMBOLIZATION
FAILURE IN HEPATOCELLULAR CARCINOMA
J. S. Evans, Department of Surgery & Cancer, Imperial College London, UK

Poster Listing
P1 PROTHROMBIN INDUCED BY VITAMIN K ABSENCE-II IN EARLY HEPATOCELLULAR CARCINOMA: A PROSPECTIVE UK COHORT EXPERIENCE
P2 FREQUENCY AND IMPACT OF EXPLANT-IMAGING DISCORDANCE ON POST LIVER TRANSPLANT OUTCOMES IN PATIENT WITH HEPATOCELLULAR CARCINOMA
P3 ANALYSIS OF SURVIVAL AND OBJECTIVE RESPONSE (OR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA IN A PHASE 3 STUDY OF LENVATINIB (REFLECT)
P4 SUBSEQUENT ANTICANCER MEDICATION FOLLOWING FIRST-LINE LENVATINIB: A POST HOC RESPONDER ANALYSIS FROM THE PHASE 3 REFLECT STUDY IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
P5 STEREOTACTIC RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA (HCC): INITIAL OUTCOMES IN ENGLAND
P6 IMPACT OF CIRRHOSIS SEVERITY ON CLINICAL OUTCOMES AFTER LOCO-REGIONAL THERAPIES FOR HEPATOCELLULAR CARCINOMA IN ENGLAND
P7 QUANTITATIVE COMPARISON OF PD-L1 IMMUNO-HISTOCHEMICAL ASSAYS IN HEPATOCELLULAR CARCINOMA: THE BLUEPRINT-HCC STUDY
P8 REAL-WORLD EXPERIENCE OF REGORAFENIB IN PATIENTS WITH HEPATOCELLULAR CANCER: A MULTICENTRE UK STUDY


Friday 15th March 2019

09:30
Registration & Coffee
09:50
Welcome
Dr Shishir Shetty, Senior Clinical Research Fellow Honorary Consultant Hepatologist, Birmingham

Session 1. Transplantation/Surgery

09:55
Update on criteria for transplant selection for HCC
Dr Abid Suddle, Kings College Hospital, London
10:10
National Allocation with a focus on liver transplantation for HCC
Dr Alex Gimson, Addenbrookes Hospital, Cambridge
10:30-11:05
Debate– Early HCC should be managed with surgical resection rather than transplantation
10:30
For
Miss Anya Adair, Royal Infirmary, Edinburgh
10:45
Against
Mr Thamara Perera, University Hospital, Birmingham
Discussion and vote
11:05
Selected Abstract Presenter - 01
11:15
Break

SESSION 2. HCC and Viral Hepatitis

11:35
Stratified Medicine for HCC surveillance in Hepatitis B/C patients (implications of DAA etc)
Professor Matthew Cramp, University Hospital, Plymouth
12:00
Immunopathogenesis of Hep B and its implications for HCC therapy
Professor Mala Maini, University College, London
12:25
Selected Abstract Presenter - 02
12:35
Lunch

SESSION 3. Oncology

13:45
New Therapeutic targets for HCC
Dr Chiang Li, Harvard Medical School
14:10
Endpoints in clinical trials of new therapies for HCC
Professor Tim Meyer, University College London
14:35
Selected Abstract presenter – 03
14:45
Selected Abstract Presenter - 04
14:55
Break

SESSION 4. Clinical Scenarios

15:15
Case Discussions: Tumour Board - Radiology/Pathology
Dr Andrew Yeoman,  Aneurin Bevan University Health Board
Dr Tahir Shah, University Hospitals, Birmingham
16:00
The impact of dietetic input in the HCC clinic
Miss Jill Johnson, University Hospitals, Birmingham
16:15
Round up and Close

BASLThe programme is endorsed by:
British Association for the Study of the Liver